Volume 10, Number 6—June 2004
Dispatch
Predominant Tuberculosis Spoligotypes, Delhi, India
Table 1
Parameters | No. (%) of patients in |
|||
---|---|---|---|---|
Clustered group | Nonclustered group | OR for clustering (95% CI) | p value | |
Age, y | ||||
15–45 | 63 (81) | 15 (19) | 4.52 (1.6 to 12.96) | 0.001 |
>46 | 13 (48) | 14 (52) | ||
Sex | ||||
Male | 53 (72) | 21 (28) | 0.88 (0.30 to 2.49) | NS |
Female | 23 (74) | 8 (26) | ||
HIV status | ||||
Seropositive | 2 (100) | 0 (0) | UD | |
Seronegative | 74 (72) | 29 (28) | ||
Previous history of TB | ||||
No previous therapy | 52 (80) | 13 (20) | 2.53 (0.89 to 7.22) | 0.05 |
Previously treated | 19 (61) | 12 (39) | ||
Drug resistance | ||||
Drug resistanceb | 22 (71) | 6 (29) | 1.56 (0.51 to 4.97) | NS |
Susceptible to all drugs | 54 (70) | 23 (30) | ||
Radiologic findings | ||||
Extensive cavitary | 12 (76) | 5 (24) | 1.6 (0.33 to 11.22) | NS |
Limited cavitary | 6 (60) | 4 (40) | ||
Sputum smear positive | ||||
1–10 AFB/10–100 fields | 30 (73) | 11 (27) | 0.96 (0.34 to 2.70) | NS |
>1 AFB per field | 37 (74) | 13 (26) |
aOR, odds ratio; CI, confidence interval; TB, tuberculosis; NS, not statistically significant; UD, undefined; AFB, acid-fast bacilli.
bResistance to one or more drugs.
Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.